Dianthus Therapeutics, Inc. /DE/ 8-K

What Happened

• Dianthus Therapeutics, Inc. filed an 8-K (Item 2.02) on January 12, 2026 saying its audited financial statements for the year ended December 31, 2025 are not yet available. The company disclosed a preliminary, unaudited estimate that cash, cash equivalents and short-term investments were approximately $514 million as of December 31, 2025. The presentation containing this estimate is being shared with investors and is attached as Exhibit 99.1.

Key Details

• Preliminary cash balance: ~$514 million (cash, cash equivalents and short-term investments) as of 12/31/2025.
• Status of financials: Audited financial statements for FY 2025 are not yet complete; amounts are subject to closing procedures and may change materially.
• Disclosure/Presentation: The company will present the information beginning January 12, 2026 (Item 7.01); CEO Marino Garcia will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026.
• Filing note: The estimate is preliminary and unaudited and does not provide a full picture of results of operations for the year.

Why It Matters

• This 8-K gives investors an early update on Dianthus’s liquidity position ahead of its audited FY2025 financials. A ~$514M cash-related balance is a material liquidity indicator for biotech companies, as it affects runway and development funding expectations. However, the number is preliminary and may change once year-end closing and audits are complete, so investors should wait for the final audited results before drawing firm conclusions.